Key Points
-
Patients with schizophrenia show numerous aberrant neurophysiological signals that reflect abnormal brain functions. Recent advances in neurophysiological techniques provide more extensive and sophisticated measures to evaluate these anomalies, and present unique opportunities for use as translational biomarkers.
-
Neurophysiological signals are analysed by two complementary methods: brain activations are viewed as a series of amplitude deflections that vary in time and space over the scalp, and brain activations are viewed as a sum of superimposed oscillations.
-
Abnormal neurophysiological signals in schizophrenia include the mismatch negativity, the auditory and visual P300 event-related potentials, and sensory-evoked potentials such as the auditory N1 and the visual P1. A deficit of smooth-pursuit eye movement is also present in patients with schizophrenia.
-
Measurement of neuronal synchrony by various electroencephalography data-analysis techniques has revealed anomalous neuronal network oscillations in response to sensory stimuli and during cognitive brain activities. Deficits have been reported in gamma band and beta band oscillations, as well as in slower frequencies.
-
Some of these neurophysiological measures are abnormal not only in schizophrenia, but also in other psychiatric and neurological disorders, such as bipolar disorder, autism, attention-deficit/hyperactive disorder and Alzheimer's disease. These findings reflect impairments in neuronal network activities underlying brain dysfunction shared by different CNS illnesses.
-
Several neurophysiological measures established in humans have been replicated in laboratory animals. Most importantly, these animal models can also reproduce disease-relevant pathophysiology.
-
Various neurotransmitter systems (such as dopamine, GABA (γ-aminobutyric acid), glutamate and acetylcholine) and receptors — including DA2, NMDA (N-methyl-D-aspartate), α7 nicotine and cannabinoid receptors — are implicated in abnormalities associated with schizophrenia. Modelling neurophysiological abnormalities of schizophrenia in preclinical studies offer additional options to evaluate the involvement of these neurotransmitter systems, and could reveal novel, potential therapeutic drug targets. Being phylogenetically conserved and easily quantifiable, electrophysiological signals offer exceptional translational biomarker opportunities.
Abstract
Schizophrenia represents a pervasive deficit in brain function, leading to hallucinations and delusions, social withdrawal and a decline in cognitive performance. As the underlying genetic and neuronal abnormalities in schizophrenia are largely unknown, it is challenging to measure the severity of its symptoms objectively, or to design and evaluate psychotherapeutic interventions. Recent advances in neurophysiological techniques provide new opportunities to measure abnormal brain functions in patients with schizophrenia and to compare these with drug-induced alterations. Moreover, many of these neurophysiological processes are phylogenetically conserved and can be modelled in preclinical studies, offering unique opportunities for use as translational biomarkers in schizophrenia drug discovery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tallon-Baudry, C. & Bertrand, O. Oscillatory gamma activity in humans and its role in object representation. Trends Cogn. Sci. 3, 151–162 (1999). Reviews evidence for gamma-band synchrony in humans and its possible roles, as well as methods for non-invasive measurement of neural synchrony.
Sehatpour, P., Molholm, S., Javitt, D. C. & Foxe, J. J. Spatiotemporal dynamics of human object recognition processing: an integrated high-density electrical mapping and functional imaging study of “closure” processes. Neuroimage 29, 605–618 (2006).
Winterer, G. et al. Complex relationship between BOLD signal and synchronization/desynchronization of human brain MEG oscillations. Hum. Brain Mapp. 28, 805–816 (2007).
Potter, D., Summerfelt, A., Gold, J. & Buchanan, R. W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 32, 692–700 (2006).
Swerdlow, N. R. et al. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 63, 1325–1335 (2006).
Roth, W. T. & Cannon, E. H. Some features of the auditory evoked response in schizophrenics. Arch. Gen. Psychiatry 27, 466–471 (1972).
Ford, J. M. Schizophrenia: the broken P300 and beyond. Psychophysiology 36, 667–682 (1999).
Jeon, Y. W. & Polich, J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40, 684–701 (2003).
Frodl-Bauch, T., Gallinat, J., Meisenzahl, E. M., Moller, H. J. & Hegerl, U. P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol. Psychiatry 45, 116–126 (1999).
Mathalon, D. H., Ford, J. M. & Pfefferbaum, A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol. Psychiatry 47, 434–449 (2000).
Polich, J. & Bloom, F. E. P300 and alcohol consumption in normals and individuals at risk for alcoholism. A preliminary report. Prog. Neuropsychopharmacol. Biol. Psychiatry 10, 201–210 (1986).
Hall, M. H. et al. Genetic overlap between bipolar illness and event-related potentials. Psychol. Med. 37, 667–678 (2007).
Turetsky, B. I. et al. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 33, 69–94 (2007).
Umbricht, D. S., Bates, J. A., Lieberman, J. A., Kane, J. M. & Javitt, D. C. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol. Psychiatry 59, 762–772 (2006).
Umbricht, D. et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol. Psychiatry 44, 716–725 (1998).
Umbricht, D. et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int. J. Neuropsychopharmcol. 2, 299–304 (1999).
Hall, M. H. et al. Genetic overlap between P300, P50, and duration mismatch negativity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 336–343 (2006).
Winterer, G. et al. P300 and genetic risk for schizophrenia. Arch. Gen. Psychiatry 60, 1158–1167 (2003).
Gallinat, J. et al. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol. Psychiatry 54, 40–48 (2003).
Blackwood, D. H. & Muir, W. J. Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. Neurotox. Res. 6, 35–41 (2004).
Friedman, D., Cornblatt, B., Vaughan, H. Jr. & Erlenmeyer-Kimling, L. Auditory event-related potentials in children at risk for schizophrenia: the complete initial sample. Psychiatry. Res. 26, 203–221 (1988).
Naatanen, R. Mismatch negativity: clinical research and possible applications. Int. J. Psychophysiol. 48, 179–188 (2003).
Umbricht, D. & Krljes, S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 76, 1–23 (2005).
Umbricht, D. et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol. Psychiatry 53, 1120–1131 (2003).
Javitt, D. C., Doneshka, P., Grochowski, S. & Ritter, W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch. Gen. Psychiatry 52, 550–558 (1995).
Light, G. A. & Braff, D. L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 62, 127–136 (2005).
Salisbury, D. F., Shenton, M. E., Griggs, C. B., Bonner-Jackson, A. & McCarley, R. W. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch. Gen. Psychiatry 59, 686–694 (2002).
Javitt, D. C., Shelley, A. M., Silipo, G. & Lieberman, J. A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch. Gen. Psychiatry 57, 1131–1137 (2000). Documents disturbances in both auditory and visual processing in schizophrenia as biomarkers for cognitive dysfunction.
Salisbury, D. F., Kuroki, N., Kasai, K., Shenton, M. E. & McCarley, R. W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry 64, 521–529 (2007).
Hall, M. H. et al. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav. Genet. 36, 845–857 (2006).
Michie, P. T., Innes-Brown, H., Todd, J. & Jablensky, A. V. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biol. Psychiatry 52, 749–758 (2002).
Bramon, E. et al. Mismatch negativity in schizophrenia: a family study. Schizophr. Res. 67, 1–10 (2004).
Brockhaus-Dumke, A. et al. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr. Res. 73, 297–310 (2005).
Javitt, D. C. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol. Neurootol. 5, 207–215 (2000).
Wible, C. G. et al. A functional magnetic resonance imaging study of auditory mismatch in schizophrenia. Am. J. Psychiatry 158, 938–943 (2001).
Shelley, A. M., Silipo, G. & Javitt, D. C. Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr. Res. 37, 65–79 (1999).
Gallinat, J. et al. Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage 17, 110–127 (2002).
Mulert, C. et al. Reduced event-related current density in the anterior cingulate cortex in schizophrenia. Neuroimage 13, 589–600 (2001).
Foxe, J. J., Doniger, G. M. & Javitt, D. C. Early visual processing deficits in schizophrenia: impaired P1 generation revealed by high-density electrical mapping. Neuroreport 12, 3815–3820 (2001).
Schechter, I. et al. Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. Clin. Neurophysiol. 116, 2204–2215 (2005).
Yeap, S. et al. Early visual sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives. Arch. Gen. Psychiatry 63, 1180–1188 (2006).
Butler, P. D. et al. Dysfunction of early stage visual processing in schizophrenia. Am. J. Psychiatry 158, 1126–1133 (2001).
Butler, P. D. et al. Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch. Gen. Psychiatry 62, 495–504 (2005). Demonstrates the three-way relationship between magnocellular deficits in schizophrenia, impaired NMDA activity and structural changes in optic radiations as demonstrated by diffusion tensor imaging.
Duncan, C. C. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr. Bull. 14, 199–203 (1988).
Bruder, G. et al. The time course of visuospatial processing deficits in schizophrenia: an event-related brain potential study. J. Abnorm. Psychol. 107, 399–411 (1998).
Javitt, D. C., Jayachandra, M., Lindsley, R. W., Specht, C. M. & Schroeder, C. E. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin. Neurophysiol. 111, 833–836 (2000).
Kayser, J. et al. ERP/CSD indices of impaired verbal working memory subprocesses in schizophrenia. Psychophysiology 43, 237–252 (2006).
Servan-Schreiber, D., Cohen, J. D. & Steingard, S. Schizophrenic deficits in the processing of context. A test of a theoretical model. Arch. Gen. Psychiatry 53, 1105–1112 (1996).
Barch, D. M., Carter, C. S., MacDonald, A. W. 3rd, Braver, T. S. & Cohen, J. D. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J. Abnorm. Psychol. 112, 132–143 (2003).
MacDonald, A. W. 3rd et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am. J. Psychiatry 162, 475–484 (2005).
Barch, D. M. et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 58, 280–288 (2001).
Dias, E. C., Foxe, J. J. & Javitt, D. C. Changing plans: a high density electrical mapping study of cortical control. Cereb Cortex 13, 701–715 (2003).
Dias, E. C. et al. Changing plans: neural correlates of executive control in monkey and human frontal cortex. Exp. Brain Res 174, 279–291 (2006).
Javitt, D. C., Rabinowicz, E., Silipo, G. & Dias, E. C. Encoding vs. retention: differential effects of cue manipulation on working memory performance in schizophrenia. Schizophr. Res. 91, 159–168 (2007).
Lakatos, P. et al. An oscillatory hierarchy controlling neuronal excitability and stimulus processing in the auditory cortex. J. Neurophysiol. 94, 1904–1911 (2005).
Haig, A. R. et al. Gamma activity in schizophrenia: evidence of impaired network binding? Clin. Neurophysiol. 111, 1461–1468 (2000).
Spencer, K. M. et al. Abnormal neural synchrony in schizophrenia. J. Neurosci. 23, 7407–7411 (2003).
Spencer, K. M. et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl Acad. Sci. USA 101, 17288–17293 (2004). References 57 and 58 present evidence for disturbances in stimulus-evoked and perception-related gamma oscillations in schizophrenia, and suggest relationships to particular symptoms.
Uhlhaas, P. J. et al. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J. Neurosci. 26, 8168–8175 (2006).
Winterer, G. et al. Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. Am. J. Psychiatry 161, 490–500 (2004). Is the first report on abnormal electrophysiological 'noise' as being a genetically determined risk factor for schizophrenia and cognitive deficits.
Kwon, J. S. et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch. Gen. Psychiatry 56, 1001–1005 (1999). The first direct evidence for impaired gamma-band oscillations in schizophrenia.
Spencer, K. M., Salisbury, D. F., Shenton, M. E. & McCarley, R. W. Gamma-band steady-state responses are impaired in first episode psychosis. Soc. Neurosci. Abstr. 36, 122.2 (2006).
Hong, L. E. et al. Evoked gamma band synchronization and the liability for schizophrenia. Schizophr. Res. 70, 293–302 (2004).
O'Donnell, B. F. et al. Neural synchronization deficits to auditory stimulation in bipolar disorder. Neuroreport 15, 1369–1372 (2004).
Winterer, G. et al. Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin. Neurophysiol. 111, 837–849 (2000). Is the first report on abnormal electrophysiological phase-synchrony (noise) being increased in schizophrenia and that it predicts cortical activation abnormalities in schizophrenia with high diagnostic specificity.
Krishnan, G. P. et al. Steady state visual evoked potential abnormalities in schizophrenia. Clin. Neurophysiol. 116, 614–624 (2005).
Jin, Y., Castellanos, A., Solis, E. R. & Potkin, S. G. EEG resonant responses in schizophrenia: a photic driving study with improved harmonic resolution. Schizophr. Res. 44, 213–220 (2000).
Clementz, B. A., Keil, A. & Kissler, J. Aberrant brain dynamics in schizophrenia: delayed buildup and prolonged decay of the visual steady-state response. Brain Res. Cogn. Brain Res. 18, 121–129 (2004).
Kim, D., Zemon, V., Saperstein, A., Butler, P. D. & Javitt, D. C. Dysfunction of early-stage visual processing in schizophrenia: harmonic analysis. Schizophr. Res. 76, 55–65 (2005).
Avila, M. T., Hong, L. E., Moates, A., Turano, K. A. & Thaker, G. K. Role of anticipation in schizophrenia-related pursuit initiation deficits. J. Neurophysiol. 95, 593–601 (2006).
Barnes, G. R., Barnes, D. M. & Chakraborti, S. R. Ocular pursuit responses to repeated, single-cycle sinusoids reveal behavior compatible with predictive pursuit. J. Neurophysiol. 84, 2340–2355 (2000).
Thaker, G. K. et al. A model of smooth pursuit eye movement deficit associated with the schizophrenia phenotype. Psychophysiology 40, 277–284 (2003).
Diefendor, A. R. & Dodge, R. An experimental study of the ocular reactions of the insane from photographic records. Brain 31, 451–489 (1908).
Hong, L. E. et al. Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch. Gen. Psychiatry 63, 259–264 (2006). Provides heritability estimates of the SPEM abnormality in families of schizophrenia probands.
Tusa, R. J. & Ungerleider, L. G. Fiber pathways of cortical areas mediating smooth pursuit eye movements in monkeys. Ann. Neurol. 23, 174–183 (1988).
Takagi, M., Zee, D. S. & Tamargo, R. J. Effects of lesions of the oculomotor cerebellar vermis on eye movements in primate: smooth pursuit. J. Neurophysiol. 83, 2047–2062 (2000).
Newsome, W. T., Wurtz, R. H. & Komatsu, H. Relation of cortical areas MT and MST to pursuit eye movements. II. Differentiation of retinal from extraretinal inputs. J. Neurophysiol. 60, 604–620 (1988). This with its accompanying paper dissects the SPEM function to highlight the critical role of the predictive mechanism in maintaining the image of a moving target on the fovea.
Assad, J. A. & Maunsell, J. H. Neuronal correlates of inferred motion in primate posterior parietal cortex. Nature 373, 518–521 (1995).
Tanaka, M. & Fukushima, K. Neuronal responses related to smooth pursuit eye movements in the periarcuate cortical area of monkeys. J. Neurophysiol. 80, 28–47 (1998).
Hong, L. E. et al. Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol. Psychiatry 57, 726–732 (2005). Describes neuronal circuitry that mediates the predictive smooth pursuit and provides evidence of reduced activity in this circuit in schizophrenia.
Hajos, M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol. Sci. 27, 391–398 (2006). Reviews the neurophysiological abnormalities in patients with schizophrenia and their potential use for preclinical research, with a particular emphasis on auditory gating.
Eriksson, J. & Villa, A. E. Event-related potentials in an auditory oddball situation in the rat. Biosystems 79, 207–212 (2005).
Maxwell, C. R. et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29, 739–746 (2004).
Umbricht, D. et al. Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res. 1019, 189–200 (2004).
Maxwell, C. R. et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J. Pharmacol. Exp. Ther. 316, 315–324 (2006).
Slawecki, C. J., Thomas, J. D., Riley, E. P. & Ehlers, C. L. Neonatal nicotine exposure alters hippocampal EEG and event-related potentials (ERPs) in rats. Pharmacol. Biochem. Behav. 65, 711–718 (2000).
Ehlers, C. L. & Somes, C. Long latency event-related potentials in mice: effects of stimulus characteristics and strain. Brain Res. 957, 117–128 (2002).
Pineda, J. A., Foote, S. L., Neville, H. J. & Holmes, T. C. Endogenous event-related potentials in monkey: the role of task relevance, stimulus probability, and behavioral response. Electroencephalogr. Clin. Neurophysiol. 70, 155–171 (1988).
Pineda, J. A., Foote, S. L. & Neville, H. J. Effects of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey. J. Neurosci. 9, 81–93 (1989).
Chen, C. M. et al. Functional anatomy and interaction of fast and slow visual pathways in macaque monkeys. Cereb. Cortex 17, 1561–1569 (2007).
Light, G. A., Geyer, M. A., Clementz, B. A., Cadenhead, K. S. & Braff, D. L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 157, 767–771 (2000).
Boutros, N. N., Gooding, D., Sundaresan, K., Burroughs, S. & Johanson, C. E. Cocaine-dependence and cocaine-induced paranoia and mid-latency auditory evoked responses and sensory gating. Psychiatry Res. 145, 147–154 (2006). Demonstrates reduced auditory-evoked potentials and impaired auditory gating (P50, N100, P200) in chronic cocaine abusers.
Adler, L. E. et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am. J. Psychiatry 161, 1822–1828 (2004).
Winterer, G. & Weinberger, D. R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 27, 683–690 (2004). Is a comprehensive overview on the noise concept in schizophrenia and how different molecular mechanisms (dopamine, GABA, glutamate) contribute to cortical microcircuit stability by changing neural synchrony (noise).
Harrison, P. J. & Weinberger, D. R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40–68 (2005).
Hill, S. Y. et al. Genetic association between reduced P300 amplitude and the DRD2 dopamine receptor A1 allele in children at high risk for alcoholism. Biol. Psychiatry 43, 40–51 (1998).
Anokhin, A. P., Todorov, A. A., Madden, P. A., Grant, J. D. & Heath, A. C. Brain event-related potentials, dopamine D2 receptor gene polymorphism, and smoking. Genet. Epidemiol. 17 (Suppl 1), 37–42 (1999).
Mulert, C. et al. A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology 31, 1335–1344 (2006).
Berman, S. M. et al. P300 development during adolescence: effects of DRD2 genotype. Clin. Neurophysiol. 117, 649–659 (2006).
Ehlis, A. C., Reif, A., Herrmann, M. J., Lesch, K. P. & Fallgatter, A. J. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32, 162–170 (2007).
Winterer, G. et al. COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. Neuroimage 32, 1722–1732 (2006). Demonstrates that dopamine reduces cortical noise as measured with fMRI.
Thaker, G. K., Wonodi, I., Avila, M. T., Hong, L. E. & Stine, O. C. Catechol O-methyltransferase polymorphism and eye tracking in schizophrenia: a preliminary report. Am. J. Psychiatry 161, 2320–2322 (2004).
Lin, C. H., Yu, Y. W., Chen, T. J., Tsa, S. J. & Hong, C. J. Association analysis for dopamine D2 receptor Taq1 polymorphism with P300 event-related potential for normal young females. Psychiatr. Genet. 11, 165–168 (2001).
Tsai, S. J., Yu, Y. W., Chen, T. J., Chen, M. C. & Hong, C. J. Association analysis for dopamine D3 receptor, dopamine D4 receptor and dopamine transporter genetic polymorphisms and P300 event-related potentials for normal young females. Psychiatr. Genet. 13, 51–53 (2003).
Bramon, E. et al. Is there an association between the COMT gene and P300 endophenotypes? Eur. Psychiatry 21, 70–73 (2006).
Winterer, G. et al. Prefrontal electrophysiologic “noise” and catechol-O-methyltransferase genotype in schizophrenia. Biol. Psychiatry 60, 578–584 (2006). Demonstrates that dopamine reduces electrophysiological noise.
Benes, F. M. & Berretta, S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1–27 (2001).
Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nature Rev. Neurosci. 6, 312–324 (2005). Reviews the evidence for abnormalities in inhibitory interneurons in schizophrenia.
Whittington, M. A. & Traub, R. D. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci. 26, 676–682 (2003).
Frodl-Bauch, T., Bottlender, R. & Hegerl, U. Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 40, 86–94 (1999).
Crook, J. M., Kisvarday, Z. F. & Eysel, U. T. GABA-induced inactivation of functionally characterized sites in cat striate cortex: effects on orientation tuning and direction selectivity. Vis. Neurosci. 14, 141–158 (1997).
Tadin, D., Lappin, J. S. & Blake, R. Fine temporal properties of center-surround interactions in motion revealed by reverse correlation. J. Neurosci. 26, 2614–2622 (2006).
Greenblatt, D. J., Gan, L., Harmatz, J. S. & Shader, R. I. Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. Br. J. Clin. Pharmacol. 60, 244–248 (2005).
Roschke, J. et al. Electrophysiological evidence for an inverse benzodiazepine receptor agonist in panic disorder. J. Psychiatr. Res. 33, 1–5 (1999).
Porjesz, B. et al. Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proc. Natl Acad. Sci. USA 99, 3729–3733 (2002).
Edenberg, H. J. et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 74, 705–714 (2004).
Javitt, D. C. & Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301–1308 (1991). Reviews the role of NMDA dysfunction in the pathophysiology of schizophrenia.
Coyle, J. T. & Tsai, G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int. Rev. Neurobiol. 59, 491–515 (2004).
Tsai, G. et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829–836 (1995).
Sumiyoshi, T., Jin, D., Jayathilake, K., Lee, M. & Meltzer, H. Y. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int. J. Neuropsychopharmacol. 8, 451–455 (2005).
Neeman, G. et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 162, 1738–1740 (2005).
Hashimoto, K. et al. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 767–769 (2005).
Harrison, P. J. & West, V. A. Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors. Mol. Psychiatry 11, 981–983 (2006).
Steullet, P., Neijt, H. C., Cuenod, M. & Do, K. Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137, 807–819 (2006).
Nilsson, L. K. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80, 315–322 (2005).
Kegeles, L. S. et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 48, 627–640 (2000).
Javitt, D. C. et al. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29, 300–307 (2004).
Geyer, M. A., Krebs-Thomson, K., Braff, D. L. & Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117–154 (2001).
Linn, G. S. & Javitt, D. C. Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12, 117–120 (2001).
Oranje, B., Gispen-de Wied, C. C., Verbaten, M. N. & Kahn, R. S. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol. Psychiatry 52, 887–895 (2002).
Abel, K. M., Allin, M. P., Hemsley, D. R. & Geyer, M. A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44, 729–737 (2003).
Heresco-Levy, U. et al. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr. Res. 91, 14–21 (2007).
Javitt, D. C., Steinschneider, M., Schroeder, C. E. & Arezzo, J. C. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl Acad. Sci. USA 93, 11962–11967 (1996).
Umbricht, D. et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 57, 1139–1147 (2000). References 133 and 134 demonstrate the ability of NMDA antagonists to reproduce neurophysiological markers of schizophrenia in animal and human models, respectively.
Kreitschmann-Andermahr, I. et al. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res. Cogn. Brain Res. 12, 109–116 (2001).
Umbricht, D., Koller, R., Vollenweider, F. X. & Schmid, L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51, 400–406 (2002).
Umbricht, D. et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28, 170–181 (2003).
Avila, M. T., Weiler, M. A., Lahti, A. C., Tamminga, C. A. & Thaker, G. K. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am. J. Psychiatry 159, 1490–1496 (2002).
Weiler, M. A., Thaker, G. K., Lahti, A. C. & Tamminga, C. A. Ketamine effects on eye movements. Neuropsychopharmacology 23, 645–653 (2000).
Bland, B. H., Declerck, S., Jackson, J., Glasgow, S. & Oddie, S. Septohippocampal properties of N-methyl-D-aspartate-induced theta-band oscillation and synchrony. Synapse 61, 185–197 (2007).
Leung, L. S. & Shen, B. Glutamatergic synaptic transmission participates in generating the hippocampal EEG. Hippocampus 14, 510–525 (2004).
Faulkner, H. J., Traub, R. D. & Whittington, M. A. Anaesthetic/amnesic agents disrupt beta frequency oscillations associated with potentiation of excitatory synaptic potentials in the rat hippocampal slice. Br. J. Pharmacol. 128, 1813–1825 (1999).
Freye, E., Latasch, L. & Levy, J. V. S. (+)-Ketamine attenuates increase in electroencephalograph activity and amplitude height of sensory-evoked potentials during rapid opioid detoxification. Anesth. Analg. 102, 1439–1444 (2006).
Freedman, R. et al. The genetics of sensory gating deficits in schizophrenia. Curr. Psychiatry Rep. 5, 155–161 (2003).
Adler, L. E. et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24, 189–202 (1998).
Hajos, M. et al. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 312, 1213–1222 (2005). Describes the effects of a selective α7 nicotinic receptor agonist on auditory gating and hippocampal oscillations in rats.
O'Neill, H. C., Rieger, K., Kem, W. R. & Stevens, K. E. DMXB, an α7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology 169, 332–339 (2003).
Stevens, K. E., Kem, W. R. & Freedman, R. Selective α 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol. Psychiatry 46, 1443–1450 (1999).
Stevens, K. E., Kem, W. R., Mahnir, V. M. & Freedman, R. Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136, 320–327 (1998).
Hurst, R. S. et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 25, 4396–4405 (2005).
Olincy, A. et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63, 630–638 (2006). Shows that a partial agonist on α7 nicotinic receptors improve P50 and neurocognitive function in patients with schizophrenia.
Hollander, E. et al. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol. Psychiatry 22, 1067–1078 (1987).
Callaway, E., Halliday, R., Naylor, H. & Schechter, G. Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology 85, 133–138 (1985).
Meador, K. J. Cholinergic, serotonergic, and GABAergic effects on the ERP. Electroencephalogr. Clin. Neurophysiol. Suppl. 44, 151–155 (1995).
Dierks, T., Frolich, L., Ihl, R. & Maurer, K. Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Pharmacopsychiatry 27, 72–74 (1994).
Anokhin, A. P. et al. The P300 brain potential is reduced in smokers. Psychopharmacology 149, 409–413 (2000).
Thomas, A., Iacono, D., Bonanni, L., D'Andreamatteo, G. & Onofrj, M. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin. Neuropharmacol. 24, 31–42 (2001).
Knott, V., Mohr, E., Mahoney, C., Engeland, C. & Ilivitsky, V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. Neuropsychobiology 45, 156–160 (2002).
Knott, V. J. et al. Acute nicotine fails to alter event-related potential or behavioral performance indices of auditory distraction in cigarette smokers. Nicotine Tob. Res. 8, 263–273 (2006).
Neuhaus, A. et al. Persistent dysfunctional frontal lobe activation in former smokers. Psychopharmacology 186, 191–200 (2006).
Werber, E. A., Gandelman-Marton, R., Klein, C. & Rabey, J. M. The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. J. Neural Transm. 110, 659–669 (2003).
Harrison, J. B., Buchwald, J. S., Kaga, K., Woolf, N. J. & Butcher, L. L. 'Cat P300' disappears after septal lesions. Electroencephalogr. Clin. Neurophysiol. 69, 55–64 (1988).
Tamminga, C. A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 67 (Suppl 9), 9–13 (2006).
Sherr, J. D. et al. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol. Psychiatry 52, 721–728 (2002).
Rodriguez, R., Kallenbach, U., Singer, W. & Munk, M. H. Short- and long-term effects of cholinergic modulation on gamma oscillations and response synchronization in the visual cortex. J. Neurosci. 24, 10369–10378 (2004).
Siok, C. J., Rogers, J. A., Kocsis, B. & Hajos, M. Activation of α7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur. J. Neurosci. 23, 570–574 (2006).
Buchanan, R. W., Freedman, R., Javitt, D. C., Abi-Dargham, A. & Lieberman, J. A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 33, 1120–1130 (2007).
Gray, J. A. & Roth, B. L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12, 904–922 (2007).
Dunlop, J. et al. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev. 12, 167–177 (2006).
Siuciak, J. A. et al. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52, 279–290 (2007).
Zhang, Z. J. et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 88, 102–110 (2006).
Mitchell, E. S. & Neumaier, J. F. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 108, 320–333 (2005).
Fox, G. B. et al. Pharmacological properties of ABT-239[4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313, 176–190 (2005).
Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med. 13, 1102–1107 (2007).
Menniti, F. S., Faraci, W. S. & Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nature Rev. Drug Discov. 5, 660–670 (2006).
Porteous, D. J., Thomson, P., Brandon, N. J. & Millar, J. K. The genetics and biology of DISC1 — an emerging role in psychosis and cognition. Biol. Psychiatry 60, 123–131 (2006).
D'Souza, D. C. Cannabinoids and psychosis. Int. Rev. Neurobiol. 78, 289–326 (2007).
Gill, C. H., Soffin, E. M., Hagan, J. J. & Davies, C. H. 5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology 42, 82–92 (2002).
W. E. Hoffmann, W. E., Siok, C. J., Kocsis, B. & Hajos, M. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Program No. 498.1. 2007 Neuroscience Meeting Planner. San Diego, CA. Society of Neuroscience web site [online], (2007)
Staubli, U. & Xu, F. B. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J. Neurosci. 15, 2445–2452 (1995).
Robbe, D. et al. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nature Neurosci. 9, 1526–1533 (2006).
Skosnik, P. D., Krishnan, G. P., Aydt, E. E., Kuhlenshmidt, H. A. & O'Donnell, B. F. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am. J. Psychiatry 163, 1798–1805 (2006).
Adler, L. E. et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am. J. Psychiatry 162, 386–388 (2005).
Maxwell, C. R., Kanes, S. J., Abel, T. & Siegel, S. J. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129, 101–107 (2004).
Schmidt, C. J. et al. Preclinical characterization of selective PDE10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. (in the press) (2007).
Price, G. W. et al. A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol. Psychiatry 60, 1–10 (2006).
Singer, W. Neuronal synchrony: a versatile code for the definition of relations? Neuron 24, 49–65, 111–125 (1999).
Pfurtscheller, G. & Lopes da Silva, F. H. Event-related EEG/MEG synchronization and desynchronization: basic principles. Clin. Neurophysiol. 110, 1842–1857 (1999).
Canolty, R. T. et al. High gamma power is phase-locked to theta oscillations in human neocortex. Science 313, 1626–1628 (2006).
Foxe, J. J., Murray, M. M. & Javitt, D. C. Filling-in in schizophrenia: a high-density electrical mapping and source-analysis investigation of illusory contour processing. Cereb. Cortex 15, 1914–1927 (2005).
Winterer, G. et al. Instability of prefrontal signal processing in schizophrenia. Am. J. Psychiatry 163, 1960–1968 (2006)). Is the first report on abnormal 'noise' in schizophrenia as measured with fMRI.
Braff, D. L., Geyer, M. A. & Swerdlow, N. R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156, 234–258 (2001).
Mackeprang, T., Kristiansen, K. T. & Glenthoj, B. Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol. Psychiatry 52, 863–873 (2002).
Ueki, A., Goto, K., Sato, N., Iso, H. & Morita, Y. Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. Psychiatry Clin. Neurosci. 60, 55–62 (2006).
Perry, W., Minassian, A., Feifel, D. & Braff, D. L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol. Psychiatry 50, 418–424 (2001).
Linn., G. S., Negi, S. S., Gerum, S. V. & Javitt, D. C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology 169, 234–239 (2003).
Swerdlow, N. R. et al. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology 161, 189–201 (2002).
Swerdlow, N. R. et al. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 31, 506–515 (2006). Compares neurochemical/pharmacological attributes of prepulse inhibition and auditory gating in rats.
Duncan, E. J. et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25, 72–83 (2001).
Clementz, B. A., Geyer, M. A. & Braff, D. L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am. J. Psychiatry 155, 1691–1694 (1998).
Myles-Worsley, M., Ord, L., Blailes, F., Ngiralmau, H. & Freedman, R. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia. Biol. Psychiatry 55, 663–667 (2004).
Yee, C. M., Nuechterlein, K. H., Morris, S. E. & White, P. M. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J. Abnorm. Psychol. 107, 691–698 (1998).
Cadenhead, K. S., Light, G. A., Geyer, M. A. & Braff, D. L. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am. J. Psychiatry 157, 55–59 (2000).
Cancelli, I. et al. Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease. J. Clin. Neurophysiol. 23, 421–425 (2006).
Schulze, K. K. et al. P50 Auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol. Psychiatry 62, 121–128 (2007).
Adler, L. E. et al. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. Neuropsychopharmacology 24, 671–679 (2001).
Light, G. A. et al. Amphetamine disrupts P50 suppression in normal subjects. Biol. Psychiatry 46, 990–996 (1999).
Freedman, R. et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl Acad. Sci. USA 94, 587–592 (1997).
de Bruin, N. M. et al. Sensory gating of auditory evoked potentials in rats: effects of repetitive stimulation and the interstimulus interval. Biol. Psychol. 55, 195–213 (2001).
Blackwood, D. H., St Clair, D. M., Muir, W. J. & Duffy, J. C. Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch. Gen. Psychiatry 48, 899–909 (1991).
Schreiber, H., Stolz-Born, G., Kornhuber, H. H. & Born, J. Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biol. Psychiatry 32, 634–651 (1992).
Salisbury, D. F. et al. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch. Gen. Psychiatry 55, 173–180 (1998).
Hirayasu, Y. et al. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biol. Psychiatry 43, 244–253 (1998).
Niznikiewicz, M. A. et al. Lateralized P3 deficit in schizotypal personality disorder. Biol. Psychiatry 48, 702–705 (2000).
Polich, J. & Corey-Bloom, J. Alzheimer's disease and P300: review and evaluation of task and modality. Curr. Alzheimer Res. 2, 515–525 (2005).
Lopez, V. et al. Attention-deficit hyperactivity disorder involves differential cortical processing in a visual spatial attention paradigm. Clin. Neurophysiol. 117, 2540–2548 (2006).
Galletly, C. A., Clark, C. R. & McFarlane, A. C. Clozapine improves working memory updating in schizophrenia. Eur. Neuropsychopharmacol. 15, 601–608 (2005).
Gallinat, J. et al. P300 and symptom improvement in schizophrenia. Psychopharmacology 158, 55–65 (2001).
Blum, K., Braverman, E. R., Dinardo, M. J., Wood, R. C. & Sheridan, P. J. Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. Pharmacogenetics 4, 313–322 (1994).
Ahveninen, J. et al. Scopolamine augments transient auditory 40-Hz magnetic response in humans. Neurosci. Lett. 277, 115–118 (1999).
Ahveninen, J. et al. Inherited auditory-cortical dysfunction in twin pairs discordant for schizophrenia. Biol. Psychiatry 60, 612–620 (2006).
Bar-Haim, Y., Marshall, P. J., Fox, N. A., Schorr, E. A. & Gordon-Salant, S. Mismatch negativity in socially withdrawn children. Biol. Psychiatry 54, 17–24 (2003).
Pekkonen, E., Jousmaki, V., Kononen, M., Reinikainen, K. & Partanen, J. Auditory sensory memory impairment in Alzheimer's disease: an event-related potential study. Neuroreport 5, 2537–2540 (1994).
Schall, U., Catts, S. V., Karayanidis, F. & Ward, P. B. Auditory event-related potential indices of fronto-temporal information processing in schizophrenia syndromes: valid outcome prediction of clozapine therapy in a three-year follow-up. Int. J. Neuropsychopharmcol. 2, 83–93 (1999).
Javitt, D. C., Schroeder, C. E., Steinschneider, M., Arezzo, J. C. & Vaughan, H. G., Jr. Demonstration of mismatch negativity in the monkey. Electroencephalogr. Clin. Neurophysiol. 83, 87–90 (1992).
Frangou, S. et al. The Maudsley Family Study, II: Endogenous event-related potentials in familial schizophrenia. Schizophr. Res. 23, 45–53 (1997).
Brenner, C. A., Sporns, O., Lysaker, P. H. & O'Donnell, B. F. EEG synchronization to modulated auditory tones in schizophrenia, schizoaffective disorder, and schizotypal personality disorder. Am. J. Psychiatry 160, 2238–2240 (2003).
Boutros, N. et al. Cocaine use and the mid-latency auditory evoked responses. Psychiatry Res. 96, 117–126 (2000).
O'Donnell, B. F., Vohs, J. L., Hetrick, W. P., Carroll, C. A. & Shekhar, A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int. J. Psychophysiol. 53, 45–55 (2004).
Schroeder, C. E. et al. N-methyl-D-aspartate enhancement of phasic responses in primate neocortex. Exp. Brain Res. 114, 271–278 (1997).
Wilson, T. W., Rojas, D. C., Reite, M. L., Teale, P. D. & Rogers, S. J. Children and adolescents with autism exhibit reduced MEG steady-state gamma responses. Biol. Psychiatry 62, 192–197 (2007).
Santarelli, R. et al. Effects of isoflurane on auditory middle latency (MLRs) and steady-state (SSRs) responses recorded from the temporal cortex of the rat. Brain Res. 973, 240–251 (2003).
Gallinat, J., Winterer, G., Herrmann, C. S. & Senkowski, D. Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing. Clin. Neurophysiol. 115, 1863–1874 (2004).
Ahveninen, J. et al. Suppression of transient 40-Hz auditory response by haloperidol suggests modulation of human selective attention by dopamine D2 receptors. Neurosci. Lett. 292, 29–32 (2000).
Demiralp, T. et al. DRD4 and DAT1 polymorphisms modulate human gamma band responses. Cereb. Cortex 17, 1007–1019 (2007).
Cunningham, M. O. et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 26, 2767–2776 (2006).
Holsheimer, J. Generation of theta activity (RSA) in the cingulate cortex of the rat. Exp. Brain Res. 47, 309–312 (1982).
Thaker, G. K. et al. Smooth pursuit eye movements to extraretinal motion signals: deficits in relatives of patients with schizophrenia. Arch. Gen. Psychiatry 55, 830–836 (1998).
Rosenberg, D. R. et al. Eye-tracking dysfunction in offspring from the New York High-Risk Project: diagnostic specificity and the role of attention. Psychiatry Res. 66, 121–130 (1997).
Sweeney, J. A. et al. Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields. Biol. Psychiatry 44, 698–708 (1998).
Ross, R. G. Early expression of a pathophysiological feature of schizophrenia: saccadic intrusions into smooth-pursuit eye movements in school-age children vulnerable to schizophrenia. J. Am. Acad. Child. Adolesc. Psychiatry 42, 468–476 (2003).
Litman, R. E., Hommer, D. W., Radant, A., Clem, T. & Pickar, D. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophr. Res. 12, 107–120 (1994).
Avila, M. T., Sherr, J. D., Hong, E., Myers, C. S. & Thaker, G. K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 28, 2184–2191 (2003).
Olincy, A., Johnson, L. L. & Ross, R. G. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res. 117, 223–236 (2003).
Acknowledgements
This work was supported in part by K02 MH01439 and R01 MH49,334 (D.C.J.), R03 MH76,760 and a NARSAD Young Investigator Award (K.M.S.), and RO1 MH-49826 and RO1 MH-67,014 (G.K.T.). The authors wish to thank E. Saccente for her technical assistance.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Glossary
- Local field potential
-
The summed postsynaptic potentials recorded from neurons neighbouring a microelectrode.
- Prepulse inhibition
-
(PPI). Prepulse inhibition is a measure of sensory gating in which a weak prestimulus (prepulse) reduces the startle response elicited by a subsequent intense auditory stimulus.
- P50
-
An early auditory potential reflecting initial sensory activation. P50 gating refers to the decreased P50 amplitude to the second stimulus in a paired click compared to the first.
- Prodromal symptoms
-
Symptoms that arise before the onset of fully diagnosed schizophrenia.
- Perceptual feature binding
-
The process(es) by which elemental sensory information is combined into the representation of a perception, for example, a visual object.
- Magnocellular system
-
In the primate visual system, the magnocellular system is specialized for rapid conduction of low resolution visual representations and motion information.
- Parvocellular system
-
In the primate visual system, the parvocellular system is for slow conduction of high resolution visual representations and colour.
Rights and permissions
About this article
Cite this article
Javitt, D., Spencer, K., Thaker, G. et al. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7, 68–83 (2008). https://doi.org/10.1038/nrd2463
Issue Date:
DOI: https://doi.org/10.1038/nrd2463
This article is cited by
-
Deep psychophysiological phenotyping of adolescents and adults with 22q11.2 deletion syndrome: a multilevel approach to defining core disease processes
BMC Psychiatry (2023)
-
Application of evoked response audiometry for specifying aberrant gamma oscillations in schizophrenia
Scientific Reports (2022)
-
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058
Neuropsychopharmacology (2022)
-
Evaluating delay of gamma oscillations in patients with schizophrenia using evoked response audiometry system
Scientific Reports (2022)
-
N-methyl-D-aspartate receptor antagonism impairs sensory gating in the auditory cortex in response to speech stimuli
Psychopharmacology (2022)